MECHANISMS OF AIDS PATHOGENESIS: COLLABORATIVE TEAMS Release Date: July 9, 1998 PA NUMBER: PA-98-091 P.T. National Institute of Allergy and Infectious Diseases National Cancer Institute National Center for Research Resources National Institute of Child Health and Human Development National Institute of Dental Research National Institute of Diabetes, Digestive and Kidney Diseases National Institute of Mental Health PURPOSE This Program Announcement (PA) replaces PA-96-072, Mechanisms of AIDS Pathogenesis (NIH Guide, Vol. 25, No. 30, September 6, 1996). The purpose of this PA is to solicit hypothesis-driven in vivo HIV and AIDS pathogenesis research by collaborative multidisciplinary research teams. In vivo research includes studies of human clinical or epidemiological cohorts, studies of animal models, or studies of appropriate specimens from humans or animals. Often, in vivo research requires an integrated multidisciplinary collaborative team approach involving state-of-the-art methods and approaches within the context of animal models and/or well-defined human cohorts or patient samples. Collaborative multidisciplinary research teams are defined as two or more laboratories at the same or different institutions specializing in different scientific disciplines, e.g., animal models, biochemistry, biophysics, cellular biology, epidemiology, genetics, immunology, molecular biology, gastroenterology, cancer virology, cancer biology, neurobiology, and pathology. Not within the scope of this PA are support for epidemiology cohorts, therapeutic or vaccine trials, or proposals from a single laboratory. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000,"a PHS-led national activity for setting priority areas. This PA, Mechanisms of AIDS Pathogenesis: Collaborative Teams, is related to the priority area of HIV infection. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017- 001-10473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402- 9325 (telephone 202-512-1800). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign, for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as Principal Investigators. MECHANISM OF SUPPORT Traditional research project grant (R01) applications may be submitted in response to this PA. Applicants may request up to five years of support. Responsibility for the planning, direction, and execution of the proposed research will be solely that of the applicant. Applicants are strongly encouraged to coordinate, through the use of consortium arrangements or subcontracts, integrated approaches with individuals or institutions having relevant reagents and expertise in their use, demonstrated ability in a particular area of relevant research, or access to relevant animal or patient populations. RESEARCH OBJECTIVES Examples of areas of research requiring multi-laboratory collaborative multidisciplinary research teams include but are not limited to: o Mechanisms of establishment of viral infection, including mucosal transmission o Immunological and virological events controlling primary infection o Direct and indirect mechanisms of HIV-mediated immunodeficiency; e.g., the effect of HIV infection on lymphopoiesis, immune regulation, including signaling ligands, receptors, homing of T cells and their recirculation o Host and virological factors modulating latent cellular and tissue reservoirs of HIV, including compartmentalization of virus o Host factors that modulate viral infection and/or disease progression o Host and viral factors regulating interspecies transmission of HIV/SIV o Mechanisms of protection induced by attenuated viruses o Impact of vaccination on viral transmission and/or disease progression o Transgenic animal models for HIV induced immunopathogenesis o The role of viruses as factors or co-factors in the etiology, biology and pathogenesis of AIDS-associated malignancies o The genetic and molecular mechanisms leading to development of lymphomas or other malignancies in patients with HIV/AIDS The most relevant studies are expected to examine molecular and cellular biology, virology, and immunology within the context of animal models and/or well-defined human cohorts or patient samples. Studies examining HIV transmission and pathogenesis in the context of the gastrointestinal mucosal tissues are also encouraged. Investigators are encouraged to minimize the number of new animals entered into research studies (and related support expenses) by using, whenever possible, animals in ongoing supported non-human primate research. Descriptive research that is not structured around a specific hypothesis(es) is not within the scope of this PA. For example, natural history epidemiologic studies in many Division of AIDS (NIAID) supported cohorts are critically important for collecting information on the cause and course of disease. Although the information provided by such studies may provide a foundation for hypotheses that may be tested in research, this PA is intended to encourage the next step in research, the testing of these hypotheses. Clinical trials and recruitment or retention of cohorts are not encouraged under this PA. However, identified costs for patient visits, sample storage and handling specific to the applicant's proposed research are appropriate. Proposed analyses of samples acquired from epidemiologic or clinical trials are also appropriate. Investigators are encouraged to use existing supported epidemiologic or clinical cohorts instead of requesting funds to support or establish additional cohorts. Applicants are responsible for establishing collaborative arrangements. Program staff listed under INQUIRIES may be able to assist in forming collaborations and suggesting relevant cohorts or reagent resources. SPECIAL REQUIREMENTS Awardees will be invited to attend a meeting to present the progress of the work funded under this program. Details of this meeting will be provided post-award. Thus, applicants should include in their budget request funds for the PI to attend one two-day meeting per year in the Washington, DC area. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their sub-populations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification are provided that inclusion is inappropriate with respect to the health of the subjects of the purpose of the research. This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). All investigators proposing research involving human subjects should read the "NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical Research", which have been published in the Federal Register of March 28, 1994 (FR 59 14508-14513) and the NIH Guide for Grants and Contracts, Vol. 23, No. 11, March 18, 1994. Investigators may obtain copies from these sources or from the program staff listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. NIH POLICY AND GUIDELINES ON THE INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of NIH that children (i.e., individuals under the age of 21) must be included in all human subjects research, conducted or supported by the NIH, unless there are scientific and ethical reasons not to include them. This policy applies to all initial (Type 1) applications submitted for receipt dates after October 1, 1998. All investigators proposing research involving human subjects should read the "NIH Policy and Guidelines on the Inclusion of Children as Participants in Research Involving Human Subjects" that was published in the NIH Guide for Grants and Contracts, March 6, 1998, and is available at the following URL address: http://www.nih.gov/grants/guide/notice-files/not98-024.html Investigators may obtain copies from these sources or from the Program Contact person listed under INQUIRIES who may also provide additional relevant information concerning the policy. APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 5/95) and will be accepted on the standard application deadlines as indicated in the application kit. Application kits are available at most institutional offices of sponsored research and may be obtained from the Division of Extramural Outreach and Information Resources, National Institutes of Health, 6701 Rockledge Drive, MSC 7910, Bethesda, MD 20892-7910, telephone (301) 710-0267, email: grantsinfo@nih.gov. For purposes of identification and processing, item 2 on the face page of the application must be marked "YES". The PA number and the PA title must also be typed in item 2. Applications including nonhuman primate resources at the Regional Primate Research Centers (RPRC), must follow the procedures for accessing a RPRC resource published in the NIH Guide for Grants and Contracts, Vol. 25, No. 2, January 17, 1997. Briefly, applications must contain a letter from the relevant RPRC director confirming the availability of the center resources. Also, the application should provide details of any collaborative research arrangements with RPRC-based investigators. For further information contact the NCRR person listed under INQUIRIES. The completed, signed original and five legible, single-sided copies of the application and five copies of appendices must be sent or delivered to: CENTER FOR SCIENTIFIC REVIEW NATIONAL INSTITUTES OF HEALTH 6701 ROCKLEDGE DRIVE, ROOM 1040, MSC 7710 BETHESDA, MD 20892-7710 BETHESDA, MD 20817 (for express/courier service) APPLICANTS REQUESTING $500,000 OR MORE IN ANNUAL DIRECT COSTS. The NIH Policy Update on Acceptance for Review of Unsolicited Applications that Request More Than $500,000 Direct Cost for Any One Year applies to applications in response to this PA. The Policy Update was published in the NIH Guide for Grants and Contracts, March 20, 1998. Applicants from institutions that have a General Clinical Research Centers (GCRC) funded by the NIH National Center for Research Resources may wish to identify the Center as a resource for conducting the proposed research. If so, a letter of agreement from the GCRC Program Director must be included in the application material. REVIEW CONSIDERATIONS Review Procedures Applications will be assigned on the basis of established PHS referral guidelines. Upon receipt, applications will be reviewed for completeness by the NIH Center for Scientific Review. Incomplete applications will be returned to the applicant without further consideration. Applications will be reviewed for scientific and technical merit by study sections of the Center for Scientific Review, NIH, in accordance with the standard NIH peer review procedures. As part of the initial merit review, all applications will receive a written critique and undergo a process in which only those applications deemed to have the highest scientific merit, generally the top half of the applications under review, will be discussed, assigned a priority score, and receive a second level review by the appropriate national advisory council. Review Criteria The five criteria to be used in the evaluation of grant applications are listed below. To put those criteria in context, the following information is contained in instructions to the peer reviewers. The goals of NIH-supported research are to advance our understanding of biological systems, improve the control of disease, and enhance health. The reviewers will comment on the following aspects of the application in their written critiques in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals. Each of these criteria will be addressed and considered by the reviewers in assigning the overall score weighting them as appropriate for each application. Note that the application does not need to be strong in all categories to be judged likely to have a major scientific impact and thus deserve a high priority score. For example, an investigator may propose to carry out important work that by its nature is not innovative but is essential to move a field forward. 1. Significance. Does this study address an important problem? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of these studies on the concepts or methods that drive this field? 2. Approach. Are the conceptual framework, design, collaborative arrangements, methods, subjects and materials appropriate to accomplish goals of the proposed work? Does the applicant acknowledge potential problem areas and consider alternative strategies? 3. Innovation. Does the project employ novel concepts, approaches or methods? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies? 4. Investigator. Considering their respective backgrounds and proposed roles, are the proposed personnel qualified to perform the study? 5. Environment. Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? The initial review group will also examine: the appropriateness of proposed project budget and duration; the adequacy of plans to include both genders, minorities and their subgroups, and children as appropriate for the scientific goals of the research and plans for the recruitment and retention of subjects; the provisions for the protection of human and animal subjects; and the safety of the research environment. AWARD CRITERIA Applications will compete for available funds with all other favorably recommended applications. The following will be considered when making funding decisions: quality of the proposed project as determined by peer review, program balance among research areas of the program announcement, and availability of funds. INQUIRIES Written and telephone inquiries are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Inquiries regarding programmatic issues may be directed to: Opendra K. Sharma, Ph.D. Division of AIDS National Institute of Allergy and Infectious Diseases Solar Building, Room 2C04 - MSC 7620 Bethesda, MD 20892-7620 Telephone: (301) 496-9041 FAX: (301) 402-3211 Email: os4g@nih.gov Kenneth J. Cremer, Ph.D. Division of Cancer Biology National Cancer Institute Executive Plaza North 540 - MSC 7398 Bethesda, MD 20892-7398 Telephone: (301) 496-6085 FAX: (301) 496-2025 Email: kc47i@nih.gov Jerry A. Robinson, Ph.D. Regional Primate Research Centers and AIDS Models Programs National Center for Research Resources 6705 Rockledge Drive, Suite 6030 - MSC 7965 Bethesda, MD 20892-7965 Telephone: (301) 435-0744 FAX: (301) 480-3819 Email: jerryR@ep.ncrr.nih.gov Anne Willoughby, M.D., M.P.H. Center for Research for Mothers and Children National Institute of Child Health and Human Development 6100 Executive Boulevard, Room 4B11 - MSC 7510 Bethesda, MD 20892-7510 Telephone: (301) 496-7339 FAX: (301) 496-8678 Email: aw55g@nih.gov Eleni Kousvelari, D.D.S., D. Sc. Division of Extramural Research National Institute of Dental Research Building 45, Room 4AN-18A Bethesda, MD 20892-6402 Telephone: (301) 594-2427 FAX: (301) 480-8318 Email: kousvelari@de45.nidr.nih.gov Thomas F. Kresina, Ph.D. Division of Digestive Diseases and Nutrition National Institute of Diabetes, Digestive and Kidney Diseases Building 45 , Room 6AN-12A Bethesda, MD 20892-6600 Telephone: (301) 594-8871 FAX: (301) 480-8300 Email: tk13v@nih.gov Dianne M. Rausch, Ph.D. Office of AIDS Research National Institute of Mental Health 5600 Fishers Lane, Room 18-101 Rockville, MD 20857 Telephone: (301) 443-6100 FAX: (301) 443-9719 Email: dr89b@nih.gov Direct inquiries regarding fiscal matters to: Ms. Jackie Johnson Division of Extramural Activities National Institute of Allergy and Infectious Diseases Solar Building, Room 4C16 - MSC 7610 Bethesda, MD 20892-7610 Telephone: (301) 402-5936 FAX: (301) 480-3780 Email: jj19e@nih.gov AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.856, 93.855, 93.242, and 93.121. Awards are made under authorization of the Public Health Service Act, Sec. 301(c), Public Law 78-410, as amended. Awards will be administered under PHS grants policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems review. The PHS strongly encourages all grant and contract recipients to provide a smoke- free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care, or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.
Return to NIH Guide Main Index
![]() |
Office of Extramural Research (OER) |
![]() |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
![]() |
Department of Health and Human Services (HHS) |
![]() |
||||